Who
Jill Ann Howe
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Lineage Cell Therapeutics; Director, Biora Therapeutics.
In numbers
- Trades disclosed
- 17
- Buys
- 2
- Sells
- 0
- Bought
- $18K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 3 Nov 2021
- Last trade
- 5 Mar 2026
- Last filed
- 6 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Mar 2026filed 6 Mar 2026 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,050,000 at $0.00 | filing |
| 5 Mar 2026filed 6 Mar 2026 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,050,000 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —750,000 at $0.00 | filing |
| 26 Nov 2024filed 26 Nov 2024 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Bought | $8,85015,000 at $0.59 | filing |
| 16 Aug 2024filed 19 Aug 2024 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Bought | $9,34510,500 at $0.89 | filing |
| 5 Jun 2024filed 6 Jun 2024 | Biora Therapeuticsoption or derivative | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 5 Jun 2024filed 6 Jun 2024 | Biora Therapeutics | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 7 Mar 2024filed 8 Mar 2024 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —650,000 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | Biora Therapeuticsoption or derivative | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | Biora Therapeutics | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 9 Mar 2023filed 10 Mar 2023 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 3 Jan 2023filed 5 Jan 2023 | Biora Therapeutics | SEC FORM 4 Code D | —19 | filing |
| 14 Nov 2022filed 16 Nov 2022 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,000,000 at $0.00 | filing |
| 15 Jun 2022filed 17 Jun 2022 | Biora Therapeuticsoption or derivative | SEC FORM 4 Code A | —148,810 at $0.00 | filing |
| 15 Jun 2022filed 17 Jun 2022 | Biora Therapeutics | SEC FORM 4 Code A | —96,154 at $0.00 | filing |
| 3 Nov 2021filed 5 Nov 2021 | Progenityoption or derivative | SEC FORM 4 Code A | —82,879 at $0.00 | filing |
| 3 Nov 2021filed 5 Nov 2021 | Progenity | SEC FORM 4 Code A | —76,754 at $0.00 | filing |
News
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Shares Down 1.2% – What's Next?LCTX · dailypolitical.com · 17 Oct 2026
0 headlines in the last 90 days name Jill Ann Howe; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.